Company Overview of Broad Institute of MIT and Harvard
7 Cambridge Center
Cambridge, MA 02142
Key Executives for Broad Institute of MIT and Harvard
President and Founding Director
Associate Member and Director of Stanley Center for Psychiatric Research
Compensation as of Fiscal Year 2014.
Broad Institute of MIT and Harvard Key Developments
GE Healthcare Life Sciences and the Broad Institute of MIT and Harvard Announces the Signing of a Non-Exclusive License Agreement for CRISPR-Cas9 Gene Engineering System
Dec 5 14
GE Healthcare Life Sciences and the Broad Institute of MIT and Harvard announced the signing of a non-exclusive license agreement granting GE Healthcare Life Sciences access to intellectual property held by the Broad Institute relating to the CRISPR-Cas9 gene engineering system for research purposes. The CRISPR-Cas9 system allows scientists to modify gene expression in order to gain insights vital to the understanding of disease. The intellectual property license from the Broad Institute includes the first granted patent for the use of CRISPR technology in eukaryotic cells and is based on work described in Broad Institute core member Dr. Feng Zhang's 2013 Science paper.
Sigma-Aldrich Life Sciences Acquires the License to CRISPR Patents from Broad Institute
Dec 5 14
Sigma-Aldrich announced that it has entered into a non-exclusive license agreement with the Broad Institute of MIT and Harvard. The company's biological products and services business Sigma Life Science has licensed the CRISPR/Cas technology from the Broad Institute of MIT and Harvard. As part of the agreement, Sigma-Aldrich is able to make, use and distribute the advanced gene editing tools for numerous research applications, including the generation of modified plant and animal models, custom cell line creation and for CRISPR/Cas arrayed and pooled genetic screening. This agreement enables Sigma-Aldrich to pair its lentiviral manufacturing core competency and genome editing expertise with CRISPR to create the next generation of screening tools: pre-designed or customizable individual lentiviral CRISPR clones and off-the-shelf or custom lentiviral CRISPR pools. Its first offering is a collection of clones targeting the human kinome, a significant group of genes that are commonly involved in cancer and development.
BioMed Realty Trust Inc. and Broad Institute of MIT and Harvard Form Strategic Partnership to Promote Innovation and Collaboration Within the Life Science Industry
Nov 19 14
BioMed Realty Trust Inc. and the Broad Institute of MIT and Harvard announced a strategic partnership to foster innovation and promote relationships between academia and the life science industry. This partnership brings together one of the most innovative research organizations in the world with the leading provider of real estate to the life science industry. BioMed Realty, through its strategic investment group, BioMed Ventures, will work with the Broad Institute to engage the biomedical community through several events designed to bring together thought leaders from academia, biotech and pharmaceutical companies and the investment community to stimulate conversations across their networks.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries